Details for New Drug Application (NDA): 202855
✉ Email this page to a colleague
NDA 202855 describes ZOLMITRIPTAN, which is a drug marketed by Padagis Israel, Alembic, Apotex Inc, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Rising, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Ani Pharms, Aurobindo Pharma, Invagen Pharms, Natco Pharma Usa, Orbion Pharms, Pld Acquisitions Llc, Somerset Theraps Llc, Sun Pharma Global, and Zydus Pharms, and is included in twenty-three NDAs. It is available from twenty suppliers. Additional details are available on the ZOLMITRIPTAN profile page.
The generic ingredient in ZOLMITRIPTAN is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
The generic ingredient in ZOLMITRIPTAN is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 202855
| Tradename: | ZOLMITRIPTAN |
| Applicant: | Rising |
| Ingredient: | zolmitriptan |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 2.5MG | ||||
| Approval Date: | Sep 20, 2019 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, ORALLY DISINTEGRATING;ORAL | Strength | 5MG | ||||
| Approval Date: | Sep 20, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
